### Analysis:

The earnings call for Acceleron Pharma revealed a mix of positive and cautious signals. The company reported strong financial performance, with a significant cash position and a robust pipeline of drugs in development. The management highlighted the progress in key trials and the potential for significant growth in the coming years. However, there were also concerns about the competitive landscape and the need for regulatory approval. The stock market is likely to react positively to the strong pipeline and financial position, but it may be cautious about the competitive landscape and the potential for regulatory hurdles.

### Conclusion:

The short-term impact on the stock price is likely to be positive due to the strong pipeline and financial performance. However, there may be some volatility as the market digests the competitive landscape and regulatory concerns.

**Rating: 1**